Treatment strategies for chronic hepatitis C virus infection.
Kasahara
A
A
Department of General Medicine, Osaka University Hospital, Suita, Japan.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000209:etiology; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use; D019695:Glycyrrhizic Acid / Q000627:therapeutic use; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D019190:Iron Overload / Q000628:therapy; D008113:Liver Neoplasms / Q000209:etiology; D012254:Ribavirin / Q000627:therapeutic use; D016896:Treatment Outcome; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000998:Antiviral Agents; D004365:Drugs, Chinese Herbal; D012254:Ribavirin; C018142:saiko-keishi-to; D019695:Glycyrrhizic Acid; D014580:Ursodeoxycholic Acid; D007372:Interferons